Clinical Study

Melatonin Levels in Serum and Ascitic Fluid of Patients with Hepatic Encephalopathy

Cezary Chojnacki, Marek Romanowski, Katarzyna Winczyk, Janusz Błasiak, and Jan Chojnacki

1 Department of Gastroenterology, Medical University of Lodz, 1 Haller’s Square, 90-647 Lodz, Poland
2 Department of Neuroendocrinology, Medical University of Lodz, 1/3 Sterlinga street, 91-425 Lodz, Poland
3 Department of Molecular Genetics, University of Lodz, 141/143 Pomorska street, 90-237 Lodz, Poland

Correspondence should be addressed to Jan Chojnacki, gastrologia@umed.lodz.pl

Received 16 August 2012; Accepted 4 December 2012

Copyright © 2012 Cezary Chojnacki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cirrhotic patients exhibit disturbed melatonin homeostasis, which may lead to sleep disturbances, but an influence on the hepatic encephalopathy has not been elucidated.

Aim. In the present study, the association of melatonin levels in serum and ascitic fluid and ammonia concentration related to the intensity of hepatic encephalopathy (HE) was investigated.

Material and Methods. The study included 90 alcoholic patients with hepatic encephalopathy and 30 healthy volunteers (C). Patients were divided in three groups according to 0–4 West-Haven Score: HE1 (n = 28); HE2 (n = 30), and HE3 (n = 32). Melatonin was measured by radioimmune assay. Results. In fasting patients with hepatic encephalopathy we noted higher melatonin serum levels [pg/mL] than in healthy subjects groups: C—11.3 ± 3.9, HE1—34.3 ± 12.2 (P < 0.01), HE2—54.8 ± 23.9, and HE3—119.8 ± 96.4 (P < 0.001). No correlation between melatonin and ammonia levels was found. Melatonin was detected in ascetic fluid in 24 patients of group HE2 and 27 patients of group HE3 of hepatic encephalopathy. Conclusions. Our results suggest that high blood levels of melatonin in cirrhotic liver patients may account for some of the clinical manifestations of hepatic encephalopathy, for example, daytime sleepiness, fatigue.

1. Introduction

Hepatic encephalopathy (HE) is a complex neuropsychiatric syndrome which is characterized by disturbances in behavioral and consciousness as well as neurological symptoms. Detailed pathophysiology of this disease remains unknown, but some of the pathogenetic factors have been identified. This includes disturbances of hepatocyte function because of toxic substances produced during metabolism. As result, toxic substances are transported via the blood from the portal vein into various organs including brain where they induce metabolic disturbances.

Ammonia has been identified as a factor of hepatic encephalopathy pathogenesis. It disturbs enzymatic processes in brain tissue, inhibits the activity of acetylcholine and dopamine, and increases accumulation of false neurotransmitters [1]. However, high levels of ammonia were not observed in all hepatic encephalopathy patients, indicating that other chemical substances should be also considered as pathogenetic factors. Possible candidates are the excess of methionine and its mercaptan derivatives as well as aromatic amino acids (phenylalanine, tyrosine, tryptophan, and methionine). These agents block the synthesis of physiological neurotransmitters and induce the production of false ones, including octopamine, which may replace normal neurotransmitters, especially noradrenaline and dopamine in synapses. This causes muscle tremors and psychoemotional disturbances [2, 3]. Disturbances in consciousness may also be a consequence of increased concentration of some neurotransmitters, including gamma-aminobutyric acid (GABA) and other biologically active compounds. Melatonin has beneficial effects on a variety of central nervous system (CNS) diseases [4, 5]. However, the influence of melatonin on CNS in individuals with liver insufficiency has not been sufficiently recognized.
Melatonin is released by the pineal gland according to the circadian rhythm, and its peak levels are near the middle of the dark phase [6]. Nocturnal concentrations of melatonin are severalfold higher than in the daytime [7]. Due to its high lipophilicity melatonin released from pinealocytes easily penetrates all cells and enters the body fluids [8, 9]. The gastrointestinal tract (GIT) is also a source of melatonin, from where it is released following various stimuli, including alimentary signals. In this location it seems to be synthesized when L-tryptophan is supplied by cytochrome CYP1B1 fraction [13]. The majority of melatonin is inactivated during the first passage through the bile is extremely high [20, 21]. The melatonin receptors were observed in patients with cirrhosis [23, 24]. It was suggested that this occurred as a result of hepatic insufficiency [34]. The results of these examinations allowed for categorization of patients into group HE 1 (n = 28), HE 2 (n = 30), and HE 3 (n = 32) according to the West-Haven criteria [35].

2. Material and Methods

2.1. Patients

2.1.1. Including Criteria. Ninety liver cirrhosis patients with portal hypertension and ascites (grade B, C acc. to Child-Pugh Score) [33] and thirty sex- and age-matched healthy volunteers were enrolled in this study. The study was approved by the Local Ethics Committee (RNN272/05/KB), and each patient gave written consent. Table 1 presents general characteristics of the subjects.

| Feature/parameters | Cirrhotic patients | Healthy subjects |
|--------------------|--------------------|------------------|
| Age (years)        | 44.1 ± 9.9         | 43.1 ± 6.8       |
| Sex (F, M)         | F-24, M-66         | F-11, M-19       |
| Bilirubin (mg/dL)  | 8.3 ± 7.1          | 0.7 ± 0.2        |
| Ammonia (μg/dL)    | 90.2 ± 41.0        | 30.4 ± 8.9       |
| Albumins (g/dL)    | 3.1 ± 1.4          | 5.4 ± 0.6        |
| AST (U/L)          | 81.6 ± 78.0        | 21.0 ± 4.8       |
| ALT (U/L)          | 102.3 ± 121.6      | 23.1 ± 5.9       |
| GGTP (U/L)         | 135.6 ± 90.4       | 26.0 ± 6.1       |
| ALP (U/L)          | 49.4 ± 30.2        | 37.4 ± 10.8      |
| GFR (mL/min)       | 97.0 ± 11.9        | 108.9 ± 9.6      |

AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGTP: gamma-glutamyl transpeptidase; ALP: alkaline phosphatase; GFR: glomerular filtration rate.

2.1.2. Excluding Criteria. Viral hepatitis, hepatic coma, delirium, psychic illness, renal insufficiency, and post-surgical state.

2.2. Analytical Procedures. The following biochemical examinations were performed on the patients: blood cell count, bilirubin, urea, creatinine, ALT, AST, GGTP, ALP, glucose, cholesterol, INR, prothrombin, APTT, albumins, globulins, GFR, HBsAg, and anti-HCV. In particular, ammonia in serum was performed by enzymatic method using glutaminic dehydrogenase.

The concentration of albumins and globulins as well as the number and kind of cells was determined in ascitic fluid. Sixteen patients were additionally examined to exclude
bacterial infection. Blood was taken from basilic vein, and ascitic fluid was obtained by abdominocentesis and collected at the same time, at 09:00 h at which time the patients were in fasting state and in the daylight for 2 hrs. Three days before the examination, the patients were on the same standard diet consisting of 3 × 400 mL (1800 kcal) Nutridrink (Nutricia, Poland) (1800 kcal) and 1500 mL mineral water. Samples of serum and ascitic fluid were centrifuged and kept at −70°C until the measurement of melatonin; samples were never kept longer than 4 months before the assays were performed. The concentration of melatonin was determined with the Melatonin Direct RIA (IBL, Hamburg, Germany) kit with the detection limit 2.5 pg/mL.

2.3. Statistical Analysis. To compare serum melatonin levels among all groups the nonparametric Mann-Whitney test was applied, since the distribution of the analyzed parameters significantly differed from the normal distribution. To compare melatonin levels between groups with 1–3 degree of hepatic encephalopathy the nonparametric Kruskal-Wallis test was used with the subsequent Mann-Whitney test. The Mann-Whitney test was also used to compare melatonin concentrations in blood and ascitic fluid. The correlation between the concentrations of ammonia and melatonin in blood was evaluated by linear regression equation with the Pearson’s correlation coefficient (r). All statistical analyses were performed with the use of STATISTICA, v. 9.0 package (Tulsa, OK, USA).

3. Results

Serum melatonin level in healthy subjects was 11.3 ± 3.9 pg/mL, and it was significantly higher in cirrhotic patients and strongly depended on the degree of hepatic insufficiency (Figure 1). In patients classified into group HE1, the level of melatonin was 34.3 ± 12.2 pg/mL (P < 0.01), in group HE2—54.8 ± 23.9 pg/mL (P < 0.001), and in group HE3—119.8 ± 96.4 pg/mL (P < 0.001).

Serum ammonia concentrations (µg/dL) were in groups: C—30.4 ± 8.9, HE1—52.6 ± 26.0 (P < 0.05), HE2—74.2 ± 30.6 (P < 0.001), and HE3—109.5 ± 38.9 (P < 0.001).

We did not find any correlation between melatonin and ammonia levels in all groups of patients with hepatic encephalopathy. Value of correlation coefficient (r) in group HE1 was r = −0.157 (Figure 2), in group HE2 (r = 0.024) (Figure 3), and in group HE3 (r = 0.142) (Figure 4).

Increased melatonin concentration in ascitic fluid was detected in 24 patients out of 30 (80%) in group HE2 and 27 patients out of 32 (84.3%) in group HE3, and it was 16.4 ± 14.9 pg/mL and 45.5 ± 48.6 pg/mL, respectively (P < 0.05, Figure 5). Melatonin concentrations in both groups were about threefold lower than in serum (P < 0.001, Figure 5).

Melatonin levels in ascitic fluid of two patients of group HE3 exceeded 600 pg/mL (609 and 632 pg/mL) and were similar to their respective serum concentrations (641 and 667 pg/mL); those were excluded from the statistical analyses. The remaining 11 patients displayed no melatonin in ascitic fluid.

4. Discussion

Results of many studies suggest that melatonin, both produced in the pineal gland and GIT, reaches the liver via blood circulation. Its concentration in biliary fluid is manyfold higher than diurnal concentrations in blood [20, 21]. Melatonin fulfills many important functions before its degradation, especially in reference to antioxidative defense. Mitochondria of hepatocytes are sites of intensive metabolism which lead to detoxification of many substances which are harmful for the organism. However, these detoxification processes are associated with the release of ROS, which can damage hepatocytes. Melatonin protects these cells against detrimental action of ROS because of its multiple antioxidative actions [36–38]. Melatonin protects hepatocytes against derivatives of oxygen metabolism and improves mitochondrial functions [39]. Likewise, melatonin displays preventive properties against harmful consequences of age-related changes in oxygen metabolism in rats [40]. The hepatoprotective action of melatonin was also documented.
against ionizing radiation [41], carbon tetrachloride [42], cold storage and reperfusion [43–46], hepatotoxic compounds [47–51], and bile duct ligation [52–54]. Melatonin also exerts anti-inflammatory actions in bile ducts and the pancreas [55, 56]. These beneficial actions of melatonin are attributed to its antioxidant properties [57, 58] although its receptor-mediated effects may also be beneficial [59]. Melatonin also decreases the production of proinflammatory cytokines, IL-1β and TNF-α and inhibits fibrogenesis in the liver [60, 61]. These results suggest the possibility for testing melatonin for therapeutic purposes. Melatonin protected against fat-rich diet-induced liver cirrhosis in rats [62]. A decrease in the activity of gamma-glutamyl transpeptidase and the level of proinflammatory cytokines was observed in patients with nonalcoholic steatohepatitis (NASH) after 4 weeks of L-tryptophan (the precursor of melatonin) administration [63]. A progressive reduction in the level of aminotransferases ALT and AST has been observed in patients with NASH after daily (2 × 5 mg) melatonin administration [64]. Melatonin at a dose of 50 mg/kg body weight improved the postoperational state of patients after partial liver resection [65].

It would be expected that the highest concentration of melatonin in cirrhotic patients would occur in the morning following the night time rise. The elevated serum levels are likely due to the decrease in the metabolic clearance rate, probably related to reduced liver blood flow, lowered activity of 6 β-hydroxylase, and competition with bilirubin in the intrahepatic transport system [66]. Results obtained in various laboratories are ambiguous, however, which may result from the differences in the patient-recruiting procedures. It has been observed that morning melatonin concentrations are higher in patients with minimal hepatic insufficiency compared to patients with a higher degree of this disease [67]. The highest concentration of morning melatonin, 102 pg/mL, was observed in the study in which only patients classified into group B according to Child-Pugh criteria were enrolled. We obtained a substantially lower concentration of morning melatonin, that is, 48.7 pg/mL, in the current report performed in a similar population of patients with hepatic insufficiency (group B), but this value was significantly higher in patients with more serious hepatic insufficiency. The difference may be related to the differences between the classifications, since our group C patients displayed extreme hepatic insufficiency. Moreover, we did not observe any correlation between the results of laboratory tests and concentrations of melatonin in blood; in particular no association between the concentrations of melatonin and ammonia was seen. This may result from different degrees of disturbances in the metabolic pathway of urea and melatonin. We did observe a relationship between the degree of liver encephalopathy and melatonin concentrations; however that high daytime melatonin concentration could result in daytime sleepiness and fatigue [68–70]. The involvement of melatonin in the pathogenesis of liver encephalopathy should be considered in patients with a high melatonin concentrations both in the day and at night.

**Figure 3:** Correlation between ammonia and melatonin serum levels in cirrhotic patients with 2nd degree of hepatic encephalopathy (group HE₂) according to West-Haven Score; y: regression equation, r: correlation coefficient, statistically insignificant.

**Figure 4:** Correlation between ammonia and melatonin serum levels in cirrhotic patients with 3rd degree of hepatic encephalopathy (group HE₃) according to West-Haven Score; y: regression equation, r: correlation coefficient, statistically insignificant.

![Figure 3](image)

![Figure 4](image)

**Figure 5:** Comparison of melatonin concentration in serum and ascitic fluid in cirrhotic patients with 2nd (group HE₂, n = 24) and 3rd (group HE₃, n = 25) degrees of hepatic encephalopathy. ∗∗∗P < 0.001. There are significant differences between mean values obtained in ascitic fluid in groups HE₂ and HE₃—P < 0.01.

![Figure 5](image)
Interestingly, the great majority of patients with portal hypertension had measurable levels of melatonin in their ascitic fluid. The mechanism of its leakage of melatonin from gastrointestinal tract to peritoneal cavity is not completely clear. Also it is unknown why the concentration of melatonin in ascitic fluid in some cirrhotic patients was very high, while this indoleamine was not detected in this fluid in other patients. It is worth noting that in every case, melatonin concentration in blood was higher than in ascitic fluid. A better understanding of the transfer of GIT melatonin in the ascitic fluid may be derived from the blood, from the GIT, or from both. Certainly, in patients with hepatic insufficiency the leakage of melatonin from these two sites could occur. A better understanding of the transfer of GIT and/or blood melatonin into ascitic fluid of patients with severe liver damage should be examined in greater depth.

In summary, our results indicate that increased concentration of melatonin in blood of patients with liver cirrhosis may be the consequence of both hepatic insufficiency and transport of melatonin from gastrointestinal tract to systemic circulation through the portosystemic shunts. High concentrations of melatonin in blood may influence the clinical features of hepatic encephalopathy.

Acknowledgment

This study was supported by the Ministry of Science and Higher Education of Poland, Project NN402 4819/37.

References

[1] R. F. Butterworth, “The neurobiology of hepatic encephalopathy,” Seminars in Liver Disease, vol. 16, no. 3, pp. 235–244, 1996.
[2] K. Weissenborn, J. C. Ennen, H. Schomerus, N. Rückert, and H. Hecker, “Neuropsychological characterization of hepatic encephalopathy,” Journal of Hepatology, vol. 34, no. 5, pp. 768–773, 2001.
[3] M. Ortiz, J. Córdoba, C. Jacas, M. Flavià, R. Esteban, and J. Guardia, “Neuropsychological abnormalities in cirrhosis include learning impairment,” Journal of Hepatology, vol. 44, no. 1, pp. 104–110, 2006.
[4] Y. F. Xiong, Q. Chen, J. Chen, J. Zhou, and H. X. Wang, “Melatonin reduces the impairment of axonal transport and axonopathy induced by calycin A,” Journal of Pineal Research, vol. 50, no. 3, pp. 319–327, 2011.
[5] N. K. Singhal, G. Srivastava, D. K. Patel, S. K. Jain, and M. P. Singh, “Melatonin or silymarin reduces maneb- and paraquat-induced Parkinson’s disease phenotype in the mouse,” Journal of Pineal Research, vol. 50, no. 2, pp. 97–109, 2011.
[6] J. H. Stehle, A. Saade, O. Kawashdeh et al., “A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function, and chronobiological diseases,” Journal of Pineal Research, vol. 51, no. 1, pp. 17–43, 2011.
[7] R. J. Reiter and D. X. Tan, “What constitutes a physiological concentration of melatonin?” Journal of Pineal Research, vol. 34, no. 1, pp. 79–80, 2003.
[8] C. Venegas, J. A. Garcia, G. Escames et al., “Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations,” Journal of Pineal Research, vol. 52, no. 2, pp. 217–227, 2012.
[9] D. X. Tan, L. C. Manchester, E. Sanchez-Barcelo, M. D. Mediavilla, and R. J. Reiter, “Significance of high levels of endogenous melatonin in mammalian cerebrospinal fluid and in the central nervous system,” Current Neuropharmacology, vol. 8, no. 3, pp. 162–167, 2010.
[10] N. T. Raiklin and L. I. Kvetnoy, “Melatonin and enterochromaffin cells,” Acta Histochemica, vol. 35, no. 1, pp. 19–24, 1976.
[11] G. Huetter, B. Poeggeler, A. Reimer, and A. George, “Effect of tryptophan administration on circulating melatonin levels in chicks and rats: evidence for stimulation of melatonin synthesis and release in the gastrointestinal tract,” Life Sciences, vol. 51, no. 12, pp. 945–953, 1992.
[12] G. A. Babenik, “Gastrointestinal melatonin: localization, function, and clinical relevance,” Digestive Diseases and Sciences, vol. 47, no. 10, pp. 2336–2348, 2002.
[13] P. Gibson, J. H. Gill, P. A. Khan et al., “Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development,” Molecular Cancer Therapeutics, vol. 2, no. 6, pp. 527–534, 2003.
[14] I. M. Kvetnoy, I. E. Ingel, T. V. Kvetnaia et al., “Gastrointestinal melatonin: cellular identification and biological role,” Neuroendocrinology Letters, vol. 23, no. 2, pp. 121–132, 2002.
[15] R. J. Reiter, D. X. Tan, J. C. Mayo, R. M. Sainz, J. Leon, and D. Bandyopadhyay, “Neurally-mediated and neurally-independent beneficial actions of melatonin in the gastrointestinal tract,” Journal of Physiology and Pharmacology, vol. 54, pp. 113–125, 2003.
[16] G. A. Babenik, S. F. Pang, J. R. Cockshutt et al., “Circadian variation of portal, arterial and venous blood levels of melatonin in pigs and its relationship to food intake and sleep,” Journal of Pineal Research, vol. 28, no. 1, pp. 9–15, 2000.
[17] E. A. Lane and H. B. Noss, “Pharmacokinetics of melatonin in man: first pass hepatic metabolism,” Journal of Clinical Endocrinology and Metabolism, vol. 61, no. 6, pp. 1214–1216, 1985.
[18] G. Facciolà, M. Hidestrand, C. von Bahr, and G. Tybring, “Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes,” European Journal of Clinical Pharmacology, vol. 56, no. 12, pp. 881–888, 2001.
[19] X. Ma, J. R. Idle, K. W. Krausz, and F. J. Gonzalez, “Metabolism of melatonin by human cytochromes P450,” Drug Metabolism and Disposition, vol. 33, no. 4, pp. 489–494, 2005.
[20] D. X. Tan, L. C. Manchester, R. J. Reiter, W. Qi, M. A. Hanes, and N. J. Farley, “High physiological levels of melatonin in the bile of mammals,” Life Sciences, vol. 65, no. 23, pp. 2523–2529, 1999.
[21] M. Messner, G. Huetter, T. Lorf, G. Ramadori, and H. Schwörer, “Presence of melatonin in the human hepatobiliogastrointestinal tract,” Life Sciences, vol. 69, no. 5, pp. 543–551, 2001.
[22] S. Aust, T. Thalhammer, S. Humpelet et al., “The melatonin receptor subtype MT1 is expressed in human gallbladder epithelia,” Journal of Pineal Research, vol. 36, no. 1, pp. 43–48, 2004.
[23] A. Ardizzi, G. Grugni, G. Saglietti, and F. Morabito, “Circadian rhythm of melatonin (aMT) in liver cirrhosis,” Minerva Medica, vol. 89, no. 1–2, pp. 1–4, 1998.
[24] S. Montagnese, B. Middleton, A. R. Mani, D. J. Skene, and M. Y. Morgan, “On the origin and the consequences of circadian abnormalities in patients with cirrhosis,” American Journal of Gastroenterology, vol. 105, no. 8, pp. 1773–1781, 2010.
[26] P. C. Zee, R. Mehta, F. W. Turek, and A. T. Blei, “Portacaval anastomosis disrupts circadian locomotor activity and pineal melatonin rhythms in rats,” *Brain Research*, vol. 560, no. 1-2, pp. 17–22, 1991.

[27] D. L. Coy, R. Mehta, P. Zee, F. Salchli, F. W. Turek, and A. T. Blei, “Portal-systemic shunting and the disruption of circadian locomotor activity in the rat,” *Gastroenterology*, vol. 103, no. 1, pp. 222–228, 1992.

[28] B. Finn, V. Shah, and J. Gottstein, “Neomycin improves a disrupted circadian rhythm in rats after portacaval anastomosis,” *Hepatogastroenterology*, no. 33, 1993.

[29] J. Ducis, “Effect of ammonia and R05-4864 on melatonin release in pineal,” *Journal of Neurochemistry*, vol. 62, article A-37, 1994.

[30] P. E. Steindl, B. Finn, B. Bendok, S. Rothke, P. C. Zee, and A. T. Blei, “Disruption of the diurnal rhythm of plasma melatonin in cirrhosis,” *Annals of Internal Medicine*, vol. 123, no. 4, pp. 274–277, 1995.

[31] A. J. Levy, S. Ahmed, J. M. Latham Jackson, and R. L. Sack, “Melatonin shifts human circadian rhythms according to a phase-response curve,” *Chronobiology International*, vol. 9, no. 5, pp. 380–392, 1992.

[32] K. Celinski, P. C. Konturek, M. Slomka et al., “Altered basal and postprandial plasma melatonin, gastrin, ghrelin, leptin and insulin in patients with liver cirrhosis and portal hypertension without and with oral administration of melatonin or tryptophan,” *Journal of Pineal Research*, vol. 46, no. 4, pp. 408–414, 2009.

[33] A. Suman, D. S. Barnes, N. N. Zein, G. N. Levinthal, J. T. Connor, and W. D. Carey, “Predicting outcome after cardiac surgery in patients with cirrhosis: a comparison of Child-Pugh and MELD scores,” *Clinical Gastroenterology and Hepatology*, vol. 2, no. 8, pp. 719–723, 2004.

[34] S. Montagnese, P. Amadio, and M. Y. Morgan, “Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach,” *Metabolic Brain Disease*, vol. 19, no. 3-4, pp. 281–312, 2004.

[35] P. Ferenci, A. Lockwood, K. Mullen, R. Tarter, K. Weissennorn, and A. T. Blei, “Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998,” *Hepatology*, vol. 35, no. 3, pp. 716–721, 2002.

[36] D. X. Tan, L. D. Chen, B. Poeggeler et al., “Melatonin: a potent endogenous hydroxyl radical scavenger,” *Endocrine Journal*, vol. 1, pp. 57–60, 1993.

[37] C. Rodriguez, J. C. Mayo, R. Sainz et al., “Regulation of antioxidant enzymes: a significant role for melatonin,” *Journal of Pineal Research*, vol. 36, no. 1, pp. 1–9, 2004.

[38] A. Galano, D. X. Tan, and R. J. Reiter, “Melatonin as a natural ally against oxidative stress: a physicochemical examination,” *Journal of Pineal Research*, vol. 51, no. 1, pp. 1–16, 2011.

[39] M. E. Letelier, J. Jara-Sandoval, A. Molina-Berrios, M. Fáñez, P. Aracena-Parks, and F. Aguilera, “Melatonin protects the cytochrome P450 system through a novel antioxidant mechanism,” *Chemico-Biological Interactions*, vol. 185, no. 3, pp. 208–214, 2010.

[40] C. Castillo, V. Salazar, C. Ariznavarreta, E. Vara, and J. A. F. Tresguerres, “Effect of melatonin administration on parameters related to oxidative damage in hepatocytes isolated from old Wistar rats,” *Journal of Pineal Research*, vol. 38, no. 4, pp. 240–246, 2005.

[41] M. Koc, S. Taysi, M. E. Buyukkuroglu, and N. Bakan, “Melatonin protects rat liver against irradiation-induced oxidative injury,” *Journal of Radiation Research*, vol. 44, no. 3, pp. 211–215, 2003.

[42] W. M. Daniels, R. J. Reiter, D. Melchiorri, E. Sewerynek, M. I. Pablos, and G. G. Ortiz, “Melatonin counteracts lipoperoxidation induced by carbon tetrachloride but does not restore glucose-6 phosphatase activity,” *Journal of Pineal Research*, vol. 19, no. 1, pp. 1–6, 1995.

[43] E. Sewerynek, R. J. Reiter, D. Melchiorri, G. G. Ortiz, and A. Lewinski, “Oxidative damage in the liver induced by ischemia-reperfusion: protection by melatonin,” *Hepato-Gastroenterology*, vol. 43, no. 10, pp. 898–905, 1996.

[44] N. Bülbüller, Z. CETinkaya, M. A. Akkus et al., “The effects of melatonin and prostaglandin E1 analogue on experimental hepatic ischaemia reperfusion damage,” *International Journal of Clinical Practice*, vol. 57, pp. 857–860, 2003.

[45] M. Vairetti, A. Ferrigno, R. Bertone et al., “Exogenous melatonin enhances bile flow and ATP levels after cold storage and reperfusion in rat liver: implications for liver transplantation,” *Journal of Pineal Research*, vol. 38, no. 4, pp. 223–230, 2005.

[46] M. A. Zaouali, R. J. Reiter, S. Padrisa-Altes et al., “Melatonin protects steatotic and nonsteatotic liver grafts against cold ischemia and reperfusion injury,” *Journal of Pineal Research*, vol. 50, no. 2, pp. 213–221, 2011.

[47] V. Tahan, R. Ozaras, B. Canbakan et al., “Melatonin reduces dimethylnitrosamine-induced liver fibrosis in rats,” *Journal of Pineal Research*, vol. 37, no. 2, pp. 78–84, 2004.

[48] I. Tünez, M. C. Muñoz, M. A. Villavicencio et al., “Hepatotoxicity and neurotoxicity induced by thioacetamide: protective effects of melatonin and dimethylsulfoxide,” *Pharmacological Research*, vol. 52, no. 3, pp. 223–228, 2005.

[49] A. Cruz, F. J. Padillo, E. Torres et al., “Melatonin prevents experimental liver cirrhosis induced by thioacetamide in rats,” *Journal of Pineal Research*, vol. 39, no. 2, pp. 143–150, 2005.

[50] H. Wang, W. Wei, N. P. Wang et al., “Melatonin ameliorates carbon tetrachloride-induced hepatic fibrogenesis in rats via inhibition of oxidative stress,” *Life Sciences*, vol. 77, no. 15, pp. 1902–1915, 2005.

[51] X. Chen, C. Zhang, M. Zhao et al., “Melatonin alleviates lipopolysaccharide-induced hepatic SREBP-1c activation and lipid accumulation in mice,” *Journal of Pineal Research*, vol. 51, pp. 416–425, 2011.

[52] Y. Ohta, M. Kongo, and T. Kishikawa, “Melatonin exerts a therapeutic effect on cholestatic liver injury in rats with bile duct ligation,” *Journal of Pineal Research*, vol. 34, no. 2, pp. 119–126, 2003.

[53] F. J. Padillo, A. Cruz, C. Navarrete et al., “Melatonin prevents oxidative stress and hepatocyte cell death induced by experimental cholestasis,” *Free Radical Research*, vol. 38, no. 7, pp. 697–704, 2004.

[54] M. Esrefoglu, M. Gül, M. H. Emre, A. Polat, and M. A. Selimoglu, “Protective effect of low dose of melatonin against cholestatic oxidative stress after common bile duct ligation in rats,” *World Journal of Gastroenterology*, vol. 11, no. 13, pp. 1951–1956, 2005.

[55] A. Barlas, H. Çevik, S. Arbak et al., “Melatonin protects against pancreaticobiliary inflammation and associated remote organ injury in rats: role of neutrophils,” *Journal of Pineal Research*, vol. 37, no. 4, pp. 267–275, 2004.

[56] H. Wang, W. Wei, Y. X. Shen et al., “Protective effect of melatonin against liver injury in mice induced by Bacillus Calmette-Guerin plus lipopolysaccharide,” *World Journal of Gastroenterology*, vol. 10, no. 18, pp. 2690–2696, 2004.

[57] R. J. Reiter, S. D. Paredes, L. C. Manchester, and D. X. Tan, “Reducing oxidative/nitrosative stress: a newly-discovered
genre for melatonin,” *Critical Reviews in Biochemistry and Molecular Biology*, vol. 44, no. 4, pp. 175–200, 2009.

[58] E. Sahna, H. Parlakpinar, N. Vardi, Y. Cığremis, and A. Acet, “Efficacy of melatonin as protectant against oxidative stress and structural changes in liver tissue in pinealectomized rats,” *Acta Histochemica*, vol. 106, no. 5, pp. 331–336, 2004.

[59] A. M. Mathes, “Hepatoprotective actions of melatonin: possible mediation by melatonin receptors,” *World Journal of Gastroenterology*, vol. 16, no. 48, pp. 6087–6097, 2010.

[60] R. T. Hong, J. M. Xu, and Q. Mei, “Melatonin ameliorates experimental hepatic fibrosis induced by carbon tetrachloride in rats,” *World Journal of Gastroenterology*, vol. 15, no. 12, pp. 1452–1458, 2009.

[61] G. Taşhan, H. Akın, F. Aydoğan et al., “Melatonin ameliorates liver fibrosis induced by bile-duct ligation in rats,” *Canadian Journal of Surgery*, vol. 53, no. 5, pp. 313–318, 2010.

[62] M. Pan, Y. L. Song, J. M. Xu, and H. Z. Gan, “Melatonin ameliorates nonalcoholic fatty liver induced by high-fat diet in rats,” *Journal of Pineal Research*, vol. 41, no. 1, pp. 79–84, 2006.

[63] H. Cichoz-Lach, K. Gelinski, P. C. Konturek et al., “The effects of L-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis,” *Journal of Physiology and Pharmacology*, vol. 61, pp. 577–5780, 2010.

[64] M. Gonciarz, Z. Gonciarz, W. Bielanski et al., “The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin,” *Journal of Physiology and Pharmacology*, vol. 61, no. 6, pp. 705–710, 2010.

[65] A. Nickkhohlgh, H. Schneider, M. Sobirey et al., “The use of high-dose melatonin in liver resection is safe: first clinical experience,” *Journal of Pineal Research*, vol. 50, no. 4, pp. 381–388, 2011.

[66] H. Iguchi, K. I. Kato, and H. Ibayashi, “Melatonin serum levels and metabolic clearance rate in patients with liver cirrhosis,” *Journal of Clinical Endocrinology and Metabolism*, vol. 54, no. 5, pp. 1025–1027, 1982.

[67] D. Velissaris, V. Karamouzos, P. Polychronopoulos, and M. Karanikolas, “Chronotypology and melatonin alterations in minimal hepatic encephalopathy,” *Journal of Circadian Rhythms*, vol. 7, article 6, 2009.

[68] P. E. Steindl, B. Finn, B. Bendok et al., “Changes in the 24-hour rhythm of plasma melatonin in patients with liver cirrhosis—relation to sleep architecture,” *Wien Klin Wochenschr*, vol. 109, pp. 741–746, 1997.

[69] J. Córdoba, J. Cabrera, L. Lataif, P. Penev, P. Zee, and A. T. Blei, “High prevalence of sleep disturbance in cirrhosis,” *Hepatology*, vol. 27, no. 2, pp. 339–345, 1998.

[70] S. Montagnese, B. Middleton, A. R. Mani, D. J. Skene, and M. Y. Morgan, “Sleep and circadian abnormalities in patients with cirrhosis: features of delayed sleep phase syndrome?” *Metabolic Brain Disease*, vol. 24, no. 3, pp. 427–439, 2009.